Skip to main content
SpringerLink
Log in

Future Prospects and Therapeutic Potential of Streptogramins

  • Published:
Drugs Aims and scope Submit manuscript

Summary

Dramatic changes in the epidemiology and susceptibility patterns of Gram-positive cocci during the last decade have mandated new approaches to the management of many bacterial infections. For example, there has been a sharp increase in the incidence of infections caused by Staphylococcus aureus, particularly those resistant to methicillin (MRSA), and methicillin-resistant coagulase-negative staphylococci, particularly those associated with foreign bodies and indwelling medical devices. Additionally, the worldwide spread of Streptococcus pneumoniae strains resistant to penicillin and macrolides, and the emergence of enterococci (particularly Enterococcus faecium) resistant to vancomycin, teicoplanin and other antibiotics, present further therapeutic problems.

New antibacterial agents are urgently required to meet the challenges posed by these epidemiological trends. The semisynthetic streptogramins, a unique class of antibacterials currently under development, offer promise in the treatment of such multiresistant infections. Possible future applications include treatment of infections caused by the following organisms: MRSA, enterococci resistant to vancomycin, macrolides or lincosamides; and β-lactam-resistant streptococci. They may also prove useful as therapy for children with staphylococcal infection and patients with multiresistant infections who are unable to tolerate vancomycin, including patients with skin and soft tissue infections caused by Gram-positive pathogens, patients with osteomyelitis, foreign body associated infections, endocarditis and sepsis due to Gram-positive bacteria. Clinical trials are required to evaluate the efficacy and tolerability of streptogramins in these settings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Finland M. Changing etiology of bacterial infections as related to antibacterial therapy. J Infect Dis 1970; 122: 419–31.

    Article  PubMed  CAS  Google Scholar 

  2. Voss A, Doebbeling BN. The world wide prevalence of methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 1995; 5: 101–6.

    Article  PubMed  CAS  Google Scholar 

  3. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990; 34: 1227–31.

    Article  PubMed  CAS  Google Scholar 

  4. Geraci JE, Hermans PE. Vancomycin. Mayo Clin Proc 1983; 58: 88–91.

    PubMed  CAS  Google Scholar 

  5. Galankis N, Giamarellou H, Vlachogiannis N, et al. Poor efficacy of teicoplanin in the treatment of deep-seated staphylococcal infections? Eur J Clin Microbiol Infect Dis 1988; 7 (2): 130–4.

    Article  Google Scholar 

  6. Finch R. Antibacterial activity of quinupristin/dalfopristin (RP 59500): rationale for clinical use. Drugs 1996; 51 Suppl. 2: 31–7.

    Article  PubMed  CAS  Google Scholar 

  7. Lorian V, Femandes F. Synergistic activity of injectable streptogramin RP59500-vancomycin combination [abstract no. E126]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20; San Francisco, California: 107

  8. Kang SL, Rybak MJ. In vitro bactericidal activity of RP 59500 (quinupristin/dalfopristin; RP) alone and in various combinations against resistant strains of Enterococcus species and Staphylococcus aureus (SA) [abstract no. E121]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20; San Francisco, California: 107

  9. Desnottes JF, Diallo N. Cellular uptake and intracellular bactericidal activity of RP 59500 in murine macrophages. J Antimicrob Chemother 1992; 30 Suppl. A: 7–116.

    Google Scholar 

  10. Barrière JC, Bouanchaud DH, Desnottes JF, Paris JM. Streptogramin analogues? Expert Opin Invest Drugs 1994; 3 (2): 115–31.

    Article  Google Scholar 

  11. Etienne SD, Montay G, Le Liboux A, et al. A phase I, double-blind, placebo-controlled study of the tolerance and pharmacokinetic behaviour of RP 59500. J Antimicrob Chemother 1992; 30 Suppl. A: 123–31.

    PubMed  Google Scholar 

  12. Philpot-Howard J, Casewell M. Hospital infection control. London: Saunders Co., 1994.

    Google Scholar 

  13. Archer GL, Climo MW. Antimicrobial susceptibility of coagulase-negative staphylococci. Antimicrob Agents Chemother 1994; 38: 2231–7.

    Article  PubMed  CAS  Google Scholar 

  14. Bochud P-Y, Eggiman Ph, Calabdra Th, et al. Bacteremia due to viridans streptococci in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 1994; 18: 25–31.

    Article  PubMed  CAS  Google Scholar 

  15. Floret D, Stamm D, Chocut P, et al. Streptococcal toxic shock syndrome in children. Intensive Care Med 1992; 18: 175–6.

    Article  PubMed  CAS  Google Scholar 

  16. Gray GC, Eschamilla J, Hyams KC, et al. Hyperendemic Streptococcus pyogenes prophylaxis with penicillin G benzathine. N Engl J Med 1991; 325: 92–7.

    Article  PubMed  CAS  Google Scholar 

  17. Eliopoulos G. The ten most common questions about resistant enterococcal infections. Inf Dis Clin Prac 1995; 3: 125–9.

    Article  Google Scholar 

  18. Anonymous. Vosocomial enterococci resistant to vancomycin. United States 1989–1993. MMWR 1993; 42: 597–600.

    Google Scholar 

  19. Collins LA, Melanoski GJ, Eliopoulos GM, et al. In vitro activity of RP 59500, an injectable streptogramin antibiotic, against vancomycin-resistant, Gram-positive organisms? Antimicrob Agents Chemother 1993; 37 (3): 598–601.

    Article  PubMed  CAS  Google Scholar 

  20. Casewell MW, Seyed-Akhavani M, Wade J. In vitro activity of RP 59500 against vancomycin-resistant Enterococcus faecium also resistant to > 512 mg/L of gentamicin [abstract no. 1058]. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1993 Oct 17–20; New Orleans, Louisiana: 313

  21. Scriver SR, Tyrrell G, Willey BM. In vitro assessment of RP 59500 (RP) against vancomycin-resistant enterococci [abstract no. 1057]. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1993 Oct 17–20; New Orleans, Louisiana: 312

  22. Tucker L, Peterson L, Noskin E. Activity of 32 antimicrobial agents alone and in combination against high level vancomycin resistant to Enterococcus faecium [abstract no. 1061]. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1993 Oct 17–20; New Orleans, Louisiana: 313

  23. Tenover F. Data on file, Centers for Disease Control and Prevention, Atlanta, Georgia

  24. Mahayni R, Perri MB, Dembry LM, et al. Comparative in vitro and bactericidal activity of RP 59500 (quinupristin/dalfopristin) against multidrug resistant Enterococcus faecium [abstract no. E3]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct 4–7; Orlando, Florida: 27

  25. Silber JL, Patel M, Paul SM, et al. Statewide surveillance of isolates of vancomycin-resistant Gram-positive cocci: genotyping of vancomycin resistance and activity of quinupristin/dalfopristin (RP 59500) and other antimicrobials [abstract no. E8]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct 4–7; Orlando, Florida: 48

  26. Cerwinka S, Hoffman K, Fayocavitz S, et al. Compassionate use treatment of endocarditis with RP 59500 (quinupristin/dalfopristin). 3rd International Symposium on Modern Concepts in Endocarditis; 1995 13 Jul; Boston USA: 83

  27. Linden P, Pasculle AW, Riddler S, et al. Quinupristin/dalfopristin (RP 59500) for the treatment of serious infection due to high level vancomycin resistant Enterococcus faecium [abstract no. M68]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct 4–7; Orlando, Florida: 261

  28. Lynn WA, Clutterbuck E, Want S, et al. Treatment of CAPD-peritonitis due to glycopeptide-resistant Enterococcus faecium with quinupristin/dalfopristin. Lancet 1994; 344: 1025–6.

    Article  PubMed  CAS  Google Scholar 

  29. Hofmann J, Cetron MS, Forley MM, et al. The prevalence of drug resistant Streptococcus pneumoniae in Atlanta. N Eng J Med 1995; 333: 481–6.

    Article  CAS  Google Scholar 

  30. Henderson FW, Gilligan PH, Wait K, et al. Nasopharyngeal carriage of antibiotic-resistant pneumococci group day care? J Infect Dis 1988; 157 (2): 256–63.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unit of Infectious Diseases, Chaim Sheba Medical Center, Ministry of Health, Affiliated to the Tel Aviv University, Sackler School of Medicine, Tel Hashomer, 52621, Israel

    Ethan Rubinstein & Nathan Keller

Authors
  1. Ethan Rubinstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nathan Keller
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rubinstein, E., Keller, N. Future Prospects and Therapeutic Potential of Streptogramins. Drugs 51 (Suppl 1), 38–42 (1996). https://doi.org/10.2165/00003495-199600511-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199600511-00008

Keywords

Search

Navigation